For the millions of men managing conditions like benign prostatic hyperplasia, a routine uroflowmetry test is a clinic-bound, awkward affair. It requires a special appointment, a dedicated device, and the performance anxiety of urinating on command. The resulting single data point offers a physician a limited, episodic snapshot. MenHealth, a San Francisco-based digital health company founded in 2015, is betting that the standard smartphone microphone can turn that snapshot into a longitudinal story, all from the privacy of a patient's own bathroom.
The company's core product, MyUroflow, is an FDA-cleared Class II medical device that exists as a mobile application [MenHealth - App Store - Apple, 2026]. It uses the phone's microphone to perform spectral audio analysis on the sound of urine hitting toilet water, generating a clinical uroflowmetry curve that measures flow rate, voided volume, and time [MenHealth - Apps on Google Play, 2026]. The data is transmitted via a HIPAA-compliant remote monitoring platform, giving providers a window into day-to-day urinary function without requiring an office visit [LinkedIn, Unknown].
From Clinic Episodes to Home Monitoring
The clinical wedge is straightforward: move a diagnostic tool from a controlled, infrequent setting into the patient's daily life. In a urology clinic, a uroflowmeter is a bulky, expensive piece of equipment. MenHealth's approach effectively turns a ubiquitous consumer device into that instrument. Peer-reviewed validation work, presented at the International Continence Society, has shown the app's measurements have a strong correlation with those from a standard office uroflowmeter, with an insignificant difference in mean flow rates [MP02-10 MENHEALTH UROFLOWMETRY APP IS EQUIVALENT TO STANDARD OFFICE UROFLOWMETRY, Unknown]. This regulatory and clinical validation is the bedrock of the company's claim to offer "clinical-grade accuracy" from a smartphone [MenHealth - Apps on Google Play, 2026].
For urologists, the potential shift is meaningful. Instead of basing treatment decisions on one isolated test, they could monitor trends over weeks or months, observing how symptoms respond to medication or change naturally. The company says its platform is designed to make this easy for providers, hospitals, and health systems to adopt for remote patient monitoring [LinkedIn, Unknown]. The intended patient population is adult males, specifically those already under care for common urological conditions [MyUroflow Home Uroflowmetry Cost and Time Analysis, 2026].
The Founders and the Long Road to Clearance
MenHealth is led by co-founders Jenny Belotserkovsky, CEO, and Michal Tavrovsky, Chief Commercial Officer [jobright.ai, August 2026]. The pair are serial startup operators who have worked together since at least 2009, having previously co-founded the JFE Accelerator [About, Enargite, 2026]. Belotserkovsky's public profile emphasizes a mission to expand remote urological care to rural and underserved populations [LinkedIn, Unknown], a use case where eliminating travel to a specialist clinic could significantly improve access.
The company's timeline hints at the protracted diligence of medical device development. Founded in 2015, it spent years conducting validation studies and navigating the FDA's 510(k) clearance process, which it has now secured [MenHealth - App Store - Apple, 2026]. The public record shows no announced venture funding rounds, suggesting a bootstrap-heavy path or angel-backed development to reach this regulatory milestone.
| Co-Founder | Title | Background Note |
|---|---|---|
| Jenny Belotserkovsky | CEO | Serial founder; focuses on expanding care access [LinkedIn, Unknown]. |
| Michal Tavrovsky | Chief Commercial Officer | Co-founded JFE Accelerator with Belotserkovsky [Crunchbase, Unknown]. |
The Commercial Hurdles in a Niche Field
With regulatory clearance in hand, the company's next tests are commercial and clinical workflow integration. The digital health market is littered with FDA-cleared apps that struggled to find a scalable business model or secure consistent reimbursement. MenHealth's success hinges on convincing urology practices to incorporate a new data stream into patient management. The value proposition for providers includes more informed treatment decisions and potential efficiency gains from reduced in-person testing, but it also requires changes to established workflows and possibly navigating insurance coverage.
Furthermore, the product's scope is deliberately focused. It is cleared for use by adult males, which defines its initial market but also limits it [MyUroflow Home Uroflowmetry Cost and Time Analysis, 2026]. Expanding to other patient populations would require additional clinical validation and regulatory work. The company's recent activity, including a job posting for a Business Development & Partnerships Intern in August 2026, signals a push to build the commercial partnerships necessary for adoption [jobright.ai, August 2026].
The competitive landscape in smartphone uroflowmetry appears sparse, giving MenHealth a first-mover advantage with its FDA clearance. However, the company competes with the inertia of the existing standard of care and the economic reality of clinic-owned equipment. Its most significant challenge may not be a direct competitor, but rather the entrenched habit of episodic clinic-based testing.
What Standard Care Looks Like Today
For a man experiencing symptoms of urinary obstruction or an overactive bladder, the current diagnostic pathway is firmly anchored in the clinic. A urologist typically orders a uroflowmetry test during an office visit. The patient uses a specialized, funnel-equipped device that measures urine flow into a computer. The experience is clinical, often stressful, and provides a single data point that may not reflect the patient's typical voiding patterns at home. Treatment plans,whether for medication, minimally invasive procedures, or surgery,are frequently based on this snapshot, along with symptom questionnaires and sometimes invasive pressure-flow studies.
MenHealth's bet is that this snapshot is insufficient. By enabling frequent, at-home testing, the company aims to give clinicians and their patients a richer, more representative picture of urinary health. The disease states in focus are common but impactful: benign prostatic hyperplasia (BPH), lower urinary tract symptoms (LUTS), and other conditions affecting urinary flow in adult men. For this population, the promise is not just convenience, but better data for better decisions.
Sources
- [MenHealth - App Store - Apple, 2026] MenHealth Uroflowmetry App | https://apps.apple.com/us/app/menhealth-uroflowmetry/id6479476892
- [MenHealth - Apps on Google Play, 2026] MenHealth Uroflowmetry App | https://play.google.com/store/apps/details?id=com.menhealth.uroflowmetry&hl=en_US
- [LinkedIn, Unknown] MenHealth Company Page | https://www.linkedin.com/company/menhealth
- [MP02-10 MENHEALTH UROFLOWMETRY APP IS EQUIVALENT TO STANDARD OFFICE UROFLOWMETRY, Unknown] Conference Abstract | Source not linked in provided data
- [MyUroflow Home Uroflowmetry Cost and Time Analysis, 2026] MyUroflow Home Uroflowmetry Cost and Time Analysis | Source not linked in provided data
- [jobright.ai, August 2026] Business Development & Partnerships Intern Job Posting | https://jobright.ai/jobs/info/6a8cdaf8cde3717f9e9bf7b7b9
- [About, Enargite, 2026] About, Enargite | https://enargite.org/about
- [Crunchbase, Unknown] Michal Tavrovsky Profile | https://www.crunchbase.com/person/michal-tavrovsky